Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2000; 35:555-562
© 2000 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chandrasekar, B.
Right arrow Articles by Tanguay, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chandrasekar, B.
Right arrow Articles by Tanguay, J.-F.

Platelets and restenosis

Baskaran Chandrasekar, MDa and Jean-François Tanguay, MDa

a Division of Interventional Cardiology, Montreal Heart Institute, Montreal, Canada



View larger version (24K):

[in a new window]
 
Figure 1 Schematic representation of platelet-derived growth factors involved in neointimal proliferation after vascular injury. TxA2 = thromboxane A2; vWF = von Willebrand factor.

 


View larger version (19K):

[in a new window]
 
Figure 2 Brief representation of possible mode of action of PDGF on SMC leading to restenosis. Numbers in parentheses indicate sites of action of various anti-PDGF drugs, as listed in Table 1. (Note: because this is only a schematic representation, it is not possible to show the site of action of all the drugs listed in Table 1.) 1,2-DG = 1,2-diacylglycerol; IP3 = inositol triphosphate; PKC = protein kinase C; PTK = protein tyrosine kinase.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement